Scientific Evidence of the Beneficial Effects of Tomato Products on Cardiovascular Disease and Platelet Aggregation.

Montaña Cámara,Laura Domínguez,Rosa M Cámara,Virginia Fernández-Ruiz,Howard D Sesso,María-Cortes Sánchez-Mata

doi:10.3389/fnut.2022.849841

Abstract

Cardiovascular disease (CVD) includes a group of disorders of the heart and blood vessels that includes numerous problems, many of which are related to the process called atherosclerosis. The present work is aimed to analyze the most relevant studies examining the potentially beneficial effects of tomato products on both CVD prevention and antiplatelet aggregation as well as an European Food Safety Authority health claims evaluation on tomato and tomato products. To date, only one health claim has been approved for a concentrated extract of tomato soluble in water (WSTC) marketed under the patented name of Fruitflow® with two forms of presentation: WSTC I and II, with the following claim “helping to maintain normal platelet aggregation, which contributes to healthy blood flow.” Other studies also demonstrate similar beneficial effects for fresh tomatoes, tomato products and tomato pomace extracts.

Highlights

The World Health Organization (WHO) defines cardiovascular disease (CVD) as disorders of the heart and blood vessels originated from a chronic inflammatory vascular process that affects the wall of medium-sized arteries and ends up producing endothelial dysfunction and atherosclerosis
In order to demonstrate the beneficial effects of tomato product on lipid oxidative damage, EFSA requires in vivo studies performance
The effect appeared more pronounced among 6 untrained individuals that had Fruitflow R 90 min before the performance of intense physical activity and significantly reduced markers of inflammation, coagulation, and platelet aggregation compared with controls

Summary

Introduction

The World Health Organization (WHO) defines cardiovascular disease (CVD) as disorders of the heart and blood vessels originated from a chronic inflammatory vascular process that affects the wall of medium-sized arteries and ends up producing endothelial dysfunction and atherosclerosis. An important intermediate consequence of CVD is endothelial dysfunction, an alteration characterized by the functional loss of the vascular system that precedes the morphological changes characteristic of atherogenesis [1]. Longer-term clinical trials examining clinical cardiology outcomes often define major cardiovascular events to include non-fatal myocardial infarction, non-fatal stroke, and CVD death. In the last 30 years (1990–2019), there has been a marked and worrying increase in the number of cases (48.2%), deaths (35.7%) and disability (48.5%) due to CVD [2]

Methods

Findings

Conclusion